<DOC>
	<DOCNO>NCT00697619</DOCNO>
	<brief_summary>The purpose study assess efficacy addition zometa anti-neoplastic treatment compare anti-neoplastic treatment alone , measure primary efficacy variable SREs ( Skeletal Related Events ) assess safety nasopharyngeal patient bone metastasis randomize receive either zometa 4 mg anti-neoplastic treatment alone .</brief_summary>
	<brief_title>To Evaluate Efficacy ZOMETAÂ® Treatment Bone Metastases Patients With Stage IV Nasopharyngeal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Age &gt; 18 , either sex Histologically confirm stage IV nasopharyngeal cancer One bone metastasis least confirmed image without chemotherapy radiotherapy bone metastasis Life expectancy &gt; 6 M ECOG &lt; = 2 Adequate bone marrow reserve ( WBC &gt; 3.5 x 109/L , Neutrophile &gt; 1.5 x 109/L , Platelet 100 x 109/L , Hb &gt; 90 g/L ) Serum creatinine &lt; 2.0 mg/dL ( &lt; 1.5 time upper limit normal range laboratory study center ) Signed ICF Women pregnant lactation Patients hyperostosis Systemic treatment another cancer within year prior study entry Previous current treatment bisphosphonates , bone protecting , cytotoxic target therapy Initial serum creatinine &gt; 265 micromol/L and/or progressive renal disease Known hypersensitivity study drug drug similar chemical structure Use investigational agent within 28 day Baseline visit , participate simultaneously clinical study Severe comorbidity type may interfere assessment patient study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>